School of Medicine
Showing 61-70 of 343 Results
-
Diana Do, MD
Professor of Ophthalmology
Current Research and Scholarly InterestsDr. Do's research focuses on collaborative clinical trials to investigate novel treatments for retinal vascular diseases and ocular inflammation. She performs research to develop state of the art therapies for age-related macular degeneration, diabetic eye disease, retinal vein occlusion, retinal inflammation, and retinal detachment.
-
Alfredo Dubra, PhD
Professor of Ophthalmology
Current Research and Scholarly InterestsOur lab seeks to help the early diagnosing and monitoring progression of ocular, vascular, neurodegenerative and systemic diseases through novel non-invasive optical ophthalmic imaging. We pursue this goal through a multidisciplinary approach that integrates optics, computer science, vision science, electrical engineering and other engineering disciplines.
-
Peter R. Egbert, MD
Professor of Ophthalmology, Emeritus
Current Research and Scholarly InterestsOcular pathology of shaken baby syndrome
-
Houri Esmaeilkhanian
Visiting Instructor, Ophthalmology Research/Clinical Trials
BioDr. Esmaeilkhanian is an accomplished medical doctor who graduated from Iran University of Medical Sciences (IUMS) in 2018. Her passion for ophthalmology ignited during her medical studies, leading her to a focused research career in this field. After earning her degree, she dedicated her efforts to serving underprivileged communities while continuing her research at the Eye and Ear Research Institute of IUMS. In 2021, she advanced to the Doheny Eye Institute at UCLA, working in Prof. Vas Sadda’s lab, where she made significant contributions to research on diabetic retinopathy and age-related macular degeneration (AMD), further honing her clinical expertise. In March 2023, Dr. Esmaeilkhanian joined Byers Eye Institute, pioneering treatments for corneal injuries using innovative stem cell therapies and hydrogels. Additionally, she plays a crucial role in collaborative clinical studies involving the first FDA-approved AI device for diagnosing diabetic retinopathy impacting patient care in both the Bay Area and underserved regions.